Steven Cohen Aptevo Therapeutics Inc. Transaction History

Point72 Asset Management, L.P.

  • $44.6 Billion
  • Q2 2025

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$7.21 - $9.37 $1.14 Million - $1.49 Million
-158,737 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$3.29 - $9.73 $522,244 - $1.54 Million
158,737 New
158,737 $587,000

About Aptevo Therapeutics Inc.

APVO Quotes by TradingView
  • Ticker APVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,090,640
  • Market Cap $7.89M
  • Description
  • Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...
More about APVO
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email